MCID: CLP006
MIFTS: 42

Clopidogrel Resistance

Categories: Metabolic diseases

Aliases & Classifications for Clopidogrel Resistance

MalaCards integrated aliases for Clopidogrel Resistance:

Name: Clopidogrel Resistance 25
Cyp2c19-Related Poor Drug Metabolism 25
Poor Metabolism of Clopidogrel 25
Resistance to Clopidogrel 25

Classifications:



Summaries for Clopidogrel Resistance

Genetics Home Reference : 25 Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cell fragments called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).

MalaCards based summary : Clopidogrel Resistance, also known as cyp2c19-related poor drug metabolism, is related to drug metabolism, poor, cyp2c19-related and coronary artery anomaly. An important gene associated with Clopidogrel Resistance is CYP2C19 (Cytochrome P450 Family 2 Subfamily C Member 19), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Ticlopidine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Clopidogrel Resistance

Graphical network of the top 20 diseases related to Clopidogrel Resistance:



Diseases related to Clopidogrel Resistance

Symptoms & Phenotypes for Clopidogrel Resistance

MGI Mouse Phenotypes related to Clopidogrel Resistance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 KDR P2RY1 P2RY12 PTGS2 SELP VASP
2 homeostasis/metabolism MP:0005376 9.7 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR
3 liver/biliary system MP:0005370 9.23 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR

Drugs & Therapeutics for Clopidogrel Resistance

Drugs for Clopidogrel Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 55142-85-3 5472
2
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
4
Tirofiban Approved Phase 4 144494-65-5 60947
5
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
6
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
7
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
8
Pantoprazole Approved Phase 4 102625-70-7 4679
9
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
10
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
11
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
12
Cilostazol Approved, Investigational Phase 4,Not Applicable 73963-72-1 2754
13
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14 Atorvastatin Calcium Phase 4 134523-03-8
15 Rosuvastatin Calcium Phase 4 147098-20-2
16 Analgesics Phase 4,Phase 3,Not Applicable
17 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Cyclooxygenase Inhibitors Phase 4,Phase 3,Not Applicable
20 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
23 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
24 Hypolipidemic Agents Phase 4
25 Anticholesteremic Agents Phase 4
26 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Lipid Regulating Agents Phase 4
28 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
29 Antipyretics Phase 4,Phase 3,Not Applicable
30 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Not Applicable
32 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antirheumatic Agents Phase 4,Phase 3,Not Applicable
34 Antimetabolites Phase 4
35 Calcium, Dietary Phase 4
36 Ranitidine bismuth citrate Phase 4
37 policosanol Phase 4
38
Bismuth Phase 4 7440-69-9 16682734 105143
39 calcium heparin Phase 4
40
Histamine Phosphate Phase 4 51-74-1 65513
41 interferons Phase 4
42 Respiratory System Agents Phase 4,Not Applicable
43 Adjuvants, Immunologic Phase 4
44 Gastrointestinal Agents Phase 4
45 Neuroprotective Agents Phase 4,Not Applicable
46 Histamine Antagonists Phase 4
47 Histamine H2 Antagonists Phase 4
48 Antacids Phase 4
49 Vasodilator Agents Phase 4,Not Applicable
50 Anti-Asthmatic Agents Phase 4,Not Applicable

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
2 Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance Completed NCT00398463 Phase 4 Tirofiban;Placebo
3 Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation Completed NCT01094457 Phase 4 aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
4 Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI) Completed NCT01371058 Phase 4 high maintenance clopidogrel;routine dual antiplatelet;policosanol plus dual antiplatelet
5 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
6 Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention Completed NCT00404781 Phase 4 cilostazol in addition to aspirin and clopidogrel
7 Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects Completed NCT00930670 Phase 4 Rosuvastatin-omeprazole;Rosuvastatin-pantoprazole;Rosuvastatin-esomeprazole;Rosuvastatin-ranitidine;Atorvastatin-omeprazole;Atorvastatin-pantoprazole;Atorvastatin-esomeprazole;Atorvastatin-ranitidine
8 Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm Recruiting NCT03581409 Phase 4 Aspirin;Prasugrel;Clopidogrel;Cilostazol
9 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
10 Efficacy and Safety Study of Ticagrelor Unknown status NCT01812330 Phase 3 Clopidogrel;Ticagrelor
11 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
12 The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance Completed NCT01032668 Phase 3 Clopidogrel
13 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI). Completed NCT01109784 Phase 3 prasugrel;clopidogrel
14 Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS Completed NCT00444132 Phase 3 clopidogrel
15 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Completed NCT01155765 Phase 3 Prasugrel;Clopidogrel
16 Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment Completed NCT01304472 Phase 3 Prasugrel;Clopidogrel
17 Clopidogrel Resistance and Embolism in Carotid Artery Stenting Recruiting NCT02133989 Phase 3 Ticlopidine + Ginko biloba;Clopidogrel
18 Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Recruiting NCT03062462 Phase 2, Phase 3 Clopidogrel;ticagrelor
19 Antiplatelet Effects of Low-dose Ticagrelor and Standard-dose Clopidogrel in Chinese ACS Patients Recruiting NCT03381742 Phase 2, Phase 3 Ticagrelor;ticagrelor;ticagrelor;clopidogrel
20 Clopidogrel Pharmacogenomics Project Completed NCT01097343 Phase 2 clopidogrel 75 mg;Clopidogrel 150 mg
21 Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant Withdrawn NCT02008123 Phase 2 Primidone
22 Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel Completed NCT01396720 Phase 1 fluvoxamine;citalopharm
23 Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance Unknown status NCT01925872
24 Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk Unknown status NCT02624583
25 Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention Unknown status NCT01796873
26 Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00517478
27 Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery Unknown status NCT02184884
28 Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) Unknown status NCT01090336
29 Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent Unknown status NCT01816854
30 Multiple Electrode Aggregometry & Clopidogrel Resistance Completed NCT01991093
31 Aspirin and Clopidogrel Resistance Study Completed NCT01039480
32 Resistance on Antithrombotic Drugs in Ischemic Heart Disease Completed NCT00742430
33 Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients Completed NCT01865890
34 The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol Completed NCT00620646 Not Applicable aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
35 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention) Completed NCT02101411 clopidogrel, ticagrelor, cilostazole
36 Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting Completed NCT02310191
37 ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures Suspended NCT00593762
38 Clopidogrel Resistance and the Possibility of Its Affection Temporarily not available NCT00839345 clopidogrel

Search NIH Clinical Center for Clopidogrel Resistance

Genetic Tests for Clopidogrel Resistance

Anatomical Context for Clopidogrel Resistance

MalaCards organs/tissues related to Clopidogrel Resistance:

41
Heart, Brain, Testes

Publications for Clopidogrel Resistance

Articles related to Clopidogrel Resistance:

(show top 50) (show all 65)
# Title Authors Year
1
Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy. ( 29915438 )
2018
2
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. ( 29347970 )
2018
3
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. ( 29350207 )
2018
4
Comment on "Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients". ( 29424732 )
2018
5
Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. ( 28383427 )
2017
6
P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature. ( 28791856 )
2017
7
Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry. ( 28410858 )
2017
8
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. ( 28358842 )
2017
9
Overcoming clopidogrel resistance: Three promising novel antiplatelet drugs developed in China. ( 28817486 )
2017
10
Review of aspirin and clopidogrel resistance in peripheral arterial disease. ( 28893489 )
2017
11
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. ( 28329746 )
2017
12
A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. ( 29167499 )
2017
13
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance. ( 27774960 )
2016
14
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. ( 26828987 )
2016
15
Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome. ( 28167470 )
2016
16
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism. ( 27555873 )
2016
17
Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. ( 27594816 )
2016
18
Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( 26935114 )
2016
19
Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. ( 27347088 )
2016
20
Effect of obesity and serum leptin level on clopidogrel resistance. ( 27774962 )
2016
21
Allele Frequency Distribution of CYP2C19 Genotypes Associated with Clopidogrel Resistance in Russian Population. ( 27673643 )
2016
22
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( 26961113 )
2016
23
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( 27133299 )
2016
24
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( 26340464 )
2016
25
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance. ( 26479956 )
2016
26
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance. ( 25428265 )
2015
27
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. ( 25452814 )
2015
28
[CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES]. ( 26117917 )
2015
29
Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? ( 25893489 )
2015
30
Clopidogrel resistance after renal transplantation. ( 25792661 )
2015
31
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( 26303791 )
2015
32
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. ( 26347447 )
2015
33
Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. ( 26170954 )
2015
34
The STIB score: a simple clinical test to predict clopidogrel resistance. ( 26567810 )
2015
35
Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. ( 25322834 )
2015
36
Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. ( 25738571 )
2015
37
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( 26264906 )
2015
38
Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. ( 26272977 )
2015
39
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( 25457586 )
2014
40
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. ( 24745016 )
2014
41
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. ( 24996381 )
2014
42
Clopidogrel resistance: the way forward. ( 25443607 )
2014
43
Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. ( 25112801 )
2014
44
[Resistance to clopidogrel and polymorphism of P2RY12 and GPIIIA genes in patients with chronic coronary heart disease]. ( 24437181 )
2013
45
Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction. ( 24136585 )
2013
46
Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. ( 22721490 )
2013
47
Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance. ( 22153531 )
2012
48
Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis. ( 22589111 )
2012
49
Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis. ( 21215696 )
2011
50
Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. ( 21892403 )
2011

Variations for Clopidogrel Resistance

Expression for Clopidogrel Resistance

Search GEO for disease gene expression data for Clopidogrel Resistance.

Pathways for Clopidogrel Resistance

Pathways related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
2
Show member pathways
13.19 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3
Show member pathways
12.78 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
4
Show member pathways
12.22 CYP1A1 CYP1A2 CYP2C19 CYP2J2 CYP3A4
5
Show member pathways
12.18 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 PTGS2
6 12.02 ITGB3 P2RY1 P2RY12 VASP
7
Show member pathways
12 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 PTGS2
8 11.98 CYP2C19 CYP2C9 CYP2J2 PTGS2
9
Show member pathways
11.92 ITGB3 KDR PTGS2
10
Show member pathways
11.86 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
11 11.8 ITGB3 KDR PTGS2
12
Show member pathways
11.75 CYP1A1 CYP1A2 CYP3A4
13 11.7 ABCB1 CYP3A4 HMGCR
14
Show member pathways
11.7 CYP1A1 CYP1A2 CYP3A4 CYP3A5
15
Show member pathways
11.7 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
16
Show member pathways
11.67 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
17
Show member pathways
11.59 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
18
Show member pathways
11.58 ABCB1 CYP3A4 CYP3A5
19
Show member pathways
11.53 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
20 11.52 CYP1A1 CYP2J2 PTGS2
21 11.51 CYP1A1 CYP1A2 PTGS2
22
Show member pathways
11.4 ABCB1 CYP3A4 CYP3A5
23 11.38 CYP1A1 CYP1A2 CYP2C19
24 11.38 ABCB1 CYP1A2 CYP2C9 CYP3A4
25
Show member pathways
11.35 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
26
Show member pathways
11.34 CYP1A1 CYP1A2 CYP3A4
27 11.34 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
28
Show member pathways
11.22 CYP1A2 CYP2C9 CYP3A4
29
Show member pathways
11.22 CYP2C9 CYP2J2 PTGS2
30 11.19 CYP1A1 CYP1A2 CYP2C9 CYP3A4
31 11.14 CYP1A2 CYP3A4 CYP3A5
32 11.08 ABCB1 CYP2C9 CYP3A4
33
Show member pathways
11.01 ABCB1 CYP1A1 CYP1A2 CYP2C9 CYP3A4 CYP3A5
34 10.95 ABCB1 CYP3A4 CYP3A5 PTGS2
35 10.94 ABCB1 CYP3A4 CYP3A5
36 10.93 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5 ITGB3
37 10.91 ABCB1 CYP3A4
38 10.86 ABCB1 CYP3A4 CYP3A5
39 10.79 CYP1A1 CYP1A2
40 10.73 ABCB1 CYP3A4 CYP3A5
41 10.51 CYP2C9 CYP2J2
42 10.36 CYP2C9 CYP3A4

GO Terms for Clopidogrel Resistance

Cellular components related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.96 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
2 endoplasmic reticulum membrane GO:0005789 9.81 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 intracellular membrane-bounded organelle GO:0043231 9.61 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 lamellipodium membrane GO:0031258 9.43 ITGB3 VASP
5 filopodium membrane GO:0031527 9.4 ITGB3 VASP
6 platelet alpha granule membrane GO:0031092 9.37 ITGB3 SELP
7 organelle membrane GO:0031090 9.23 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
8 membrane GO:0016020 10.22 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2

Biological processes related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.96 ABCB1 CYP1A1 CYP1A2 PTGS2
2 xenobiotic metabolic process GO:0006805 9.91 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 CYP3A5
3 response to lipopolysaccharide GO:0032496 9.89 CYP1A1 CYP1A2 PTGS2 SELP
4 aging GO:0007568 9.87 CYP1A1 HMGCR P2RY1 PTGS2
5 response to organic cyclic compound GO:0014070 9.85 CYP1A1 CYP1A2 PTGS2
6 platelet activation GO:0030168 9.84 ITGB3 P2RY1 P2RY12
7 response to organic substance GO:0010033 9.83 CYP1A1 CYP1A2 PTGS2
8 cellular response to organic cyclic compound GO:0071407 9.8 CYP1A1 P2RY1 P2RY12
9 oxidative demethylation GO:0070989 9.78 CYP1A2 CYP2C9 CYP3A4 CYP3A5
10 omega-hydroxylase P450 pathway GO:0097267 9.76 CYP1A1 CYP1A2 CYP2C19 CYP2C9
11 heterocycle metabolic process GO:0046483 9.71 CYP1A1 CYP1A2 CYP2C19 CYP3A4
12 organic acid metabolic process GO:0006082 9.7 CYP2C19 CYP2C9 CYP2J2
13 lipid hydroxylation GO:0002933 9.69 CYP1A1 CYP3A4 CYP3A5
14 cellular response to copper ion GO:0071280 9.68 CYP1A1 CYP1A2
15 response to immobilization stress GO:0035902 9.68 CYP1A1 CYP1A2
16 calcium-mediated signaling using intracellular calcium source GO:0035584 9.67 KDR SELP
17 drug catabolic process GO:0042737 9.67 CYP1A2 CYP2C9 CYP3A4 CYP3A5
18 vitamin D metabolic process GO:0042359 9.66 CYP1A1 CYP3A4
19 G-protein coupled purinergic nucleotide receptor signaling pathway GO:0035589 9.65 P2RY1 P2RY12
20 cellular response to ATP GO:0071318 9.65 P2RY12 PTGS2
21 drug metabolic process GO:0017144 9.65 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
22 glial cell migration GO:0008347 9.64 P2RY1 P2RY12
23 negative regulation of blood vessel diameter GO:0097756 9.64 HMGCR PTGS2
24 adenosine receptor signaling pathway GO:0001973 9.62 P2RY1 P2RY12
25 negative regulation of norepinephrine secretion GO:0010700 9.62 P2RY1 P2RY12
26 monoterpenoid metabolic process GO:0016098 9.62 CYP1A2 CYP2C19 CYP2C9 CYP3A4
27 toxin metabolic process GO:0009404 9.61 CYP1A1 CYP1A2
28 hydrogen peroxide biosynthetic process GO:0050665 9.61 CYP1A1 CYP1A2
29 positive regulation of ion transport GO:0043270 9.6 P2RY1 P2RY12
30 steroid catabolic process GO:0006706 9.58 CYP1A2 CYP3A4
31 porphyrin-containing compound metabolic process GO:0006778 9.58 CYP1A1 CYP1A2
32 dibenzo-p-dioxin metabolic process GO:0018894 9.56 CYP1A1 CYP1A2
33 alkaloid catabolic process GO:0009822 9.55 CYP3A4 CYP3A5
34 exogenous drug catabolic process GO:0042738 9.55 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
35 monocarboxylic acid metabolic process GO:0032787 9.54 CYP1A2 CYP2C9
36 epoxygenase P450 pathway GO:0019373 9.35 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
37 steroid metabolic process GO:0008202 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
38 oxidation-reduction process GO:0055114 10.15 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
39 lipid metabolic process GO:0006629 10.03 CYP1A2 CYP2C9 CYP3A4 HMGCR PTGS2

Molecular functions related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.99 CYP1A1 CYP1A2 CYP2C19 CYP3A4 ITGB3 PTGS2
2 iron ion binding GO:0005506 9.91 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 steroid hydroxylase activity GO:0008395 9.8 CYP1A1 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 oxygen binding GO:0019825 9.8 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.8 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
6 aromatase activity GO:0070330 9.76 CYP1A1 CYP1A2 CYP2J2 CYP3A5
7 heme binding GO:0020037 9.76 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
8 arachidonic acid epoxygenase activity GO:0008392 9.7 CYP2C19 CYP2C9 CYP2J2
9 estrogen 16-alpha-hydroxylase activity GO:0101020 9.67 CYP1A1 CYP3A4 CYP3A5
10 caffeine oxidase activity GO:0034875 9.65 CYP1A2 CYP2C9 CYP3A4
11 G-protein coupled purinergic nucleotide receptor activity GO:0045028 9.56 P2RY1 P2RY12
12 demethylase activity GO:0032451 9.55 CYP1A1 CYP1A2
13 vitamin D 24-hydroxylase activity GO:0070576 9.54 CYP1A1 CYP3A4
14 monooxygenase activity GO:0004497 9.5 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
16 oxidoreductase activity GO:0016491 10.09 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4

Sources for Clopidogrel Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....